Cash Flow Statement

Amortization of Deferred Charges Amortization of Deferred Charges Amortizatization of Intangibles Amortizatization of Intangibles Asset Writedowns and Impairment Asset Writedowns and Impairment Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Inventory Change in Inventory Change in Receivables Change in Receivables Depreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Share-based Compensation Share-based Compensation Shares Issued

Daily Values

Growth Metrics

Others

Accumulated Depreciation & Amortization Accumulated Depreciation & Amortization Cost of Revenue EBIAT Gross Profit Leases Machine, Furnitures, Fixtures & Other Other Gross PP&E Adjustments Other Gross PP&E Adjustments Property, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - Net Shares Issued Shares Outstanding Shares Outstanding

Treace Medical Concepts (TMCI) Long-Term Debt Repayments (2021 - 2022)

Treace Medical Concepts filings provide 2 years of Long-Term Debt Repayments readings, the most recent being -$33.9 million for Q4 2022.

On a quarterly basis, Long-Term Debt Repayments changed N/A to -$33.9 million in Q4 2022 year-over-year; TTM through Dec 2023 was -$33.9 million, a N/A change, with the full-year FY2021 number at $1.8 million, changed N/A from a year prior.
Long-Term Debt Repayments hit -$33.9 million in Q4 2022 for Treace Medical Concepts, down from $33.9 million in the prior quarter.
In the past five years, Long-Term Debt Repayments ranged from a high of $33.9 million in Q2 2022 to a low of -$33.9 million in Q4 2022.